AI Unveils Tumor-Immune Landscape In Colorectal Adenocarcinoma

This content is brought to you by Leica Microsystems, a Danaher Operating Company.

Danaher Life Sciences employs AI-driven multiplexed imaging and analysis to investigate the tumor-immune landscape of colorectal adenocarcinoma (CAC), the second leading cause of cancer deaths worldwide. Using the Cell DIVE multiplexed imaging system, researchers analyzed CAC tissue with a 30-biomarker panel to explore the dynamics of immune and cancer cells within the tumor microenvironment (TME).

AI-powered tools like Aivia enabled precise cell segmentation and phenotyping, identifying over 550,000 individual cells and diverse immune phenotypes, including cytotoxic T cells, regulatory T cells (Tregs), and tumor-associated macrophages (TAMs). The phenotyping revealed a mix of pro-tumor and anti-tumor immune cells, with regulatory and suppressive populations like Tregs and TAMs linked to poor prognosis, while cytotoxic T cells and B cells were associated with antitumor immunity.

Clustering and dimensionality reduction techniques further uncovered unique cellular populations and spatial interactions, such as the proximity of TAMs to vasculature, indicating their role in promoting angiogenesis and tumor survival. These findings emphasize the value of spatial biology in understanding cancer progression, as it integrates cellular identity, spatial context, and biomarker expression.

The application note demonstrates the potential of multiplexed imaging and AI to provide actionable insights into the TME, enabling researchers to identify novel therapeutic targets. This approach offers a scalable framework for broader applications in cancer research and personalized treatment strategies.